Attached files

file filename
10-Q/A - AMENDMENT NO. 2 TO FORM 10-Q - ImmunoCellular Therapeutics, Ltd.d250302d10qa.htm
EX-31.2 - CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER UNDER SECTION 302 - ImmunoCellular Therapeutics, Ltd.d250302dex312.htm
EX-32.2 - CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER - ImmunoCellular Therapeutics, Ltd.d250302dex322.htm
EX-31.1 - CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER UNDER SECTION 302 - ImmunoCellular Therapeutics, Ltd.d250302dex311.htm

Exhibit 32.1

Certification of the Principal Executive Officer

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the “Company”) hereby certifies that, to his knowledge:

 

  (i) The Quarterly Report on Form 10-Q/A of the Company for the fiscal quarter ended June 30, 2011 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

 

  (ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 3, 2011       By:  

/s/    Manish Singh, Ph.D.

      Name:   Manish Singh, Ph.D.
      Title:   President and Chief Executive Officer